Nanobiotix (NBTX NASDAQ) stock market data APIs
$27.8179
-1.19(-4.3%)
as of October 15, 2025
Try our APIs with
free plan!
Nanobiotix Financial Data Overview
Price chart is built with
Anychart
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Prev. Close
27.8179
Open
26.629
High
28.6135
Low
26.629
52 wk Range
2.76-30.35
Market Cap
1 353 M
Shares Outstanding
48 215 K
Revenue
10 159 K
EPS
0
Beta
1.639
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nanobiotix data using free add-ons & libraries
Get Nanobiotix Fundamental Data
Nanobiotix Fundamental data includes:
- Net Revenue: 10 159 K
- EBITDA: -43 844 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-24
- EPS/Forecast: -0.3529
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nanobiotix News
New
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : ...
This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?
Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength. Shares are trading at new all-time highs. NBTX has surged 440% over the past year....
Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug
[Cancer cells vis] koto_feja Nanobiotix (NASDAQ:NBTX [https://seekingalpha.com/symbol/NBIX]) traded higher on Thursday after the French biotech announced initial results from a Phase 1 trial for JNJ-...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
